Search Results - Drug+Discovery

9 Results

Sort By:

A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate cancer cells

Prostate cancer (PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...

Published: 10/26/2023 | Inventor(s): Zhihui Qin, Liping Xu

Keywords(s): Anti-cancer, Cancer, Cancer Therapies, Drug Delivery, Drug Target, Prostate Cancer

Category(s): Medical, Diseases, Drug Discovery, Pharmaceuticals, Oncology

Drugs that disrupt interactions between ELK1 and the androgen receptor to suppress growth of both early stage and castration resistant prostate cancer

Background:Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, continued disease progression generally represents a transition to the lethal variant. In...

Published: 10/22/2019 | Inventor(s): Manohar Ratnam, Rayna Rosati, Mugdha Patki

Keywords(s):

Category(s): Life Science, Therapeutics, Oncology, Drug Discovery, Pharmaceuticals

Topical treatment with TGFbeta3 to facilitate skin and corneal wound healing in diabetic patients

Background: Diabetes affects approximately 170 million people worldwide, including 20.8 million in the USA, and by 2030 these numbers are projected to double. Diabetics often experience slow or limited wound healing. Slow wound healing allows longer time for the development of infections and can contribute to the formation of bed sores and ulcers....

Published: 9/16/2019 | Inventor(s): Fu-Shin Yu

Keywords(s): Diabetes

Category(s): Medical, Biologicals, Biomedical, Drug Discovery, Metabolic disorders, Protein/peptides, Therapeutics, Life Science

Generation of gp78 null mice

Generation of gp78 null mice WSU Tech#: 15-1291 Technology: Generation of the first preclinical experimental model system for gp78-/- C57BL/6 mice, which spontaneously develops age-related nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), linking endoplasmic reticulum-associated degradation (ERAD) to hepatosteatosis, cirrhosis,...

Published: 11/22/2021 | Inventor(s): Avraham Raz, Andrei Golovko

Keywords(s):

Category(s): Animal models, Biology, Biomedical, Biotechnology, Drug Delivery, Drug Discovery, Drug Screening, Genomics/Genetics, Life Science, Oncology, Research tools

Use of Raman Spectroscopy to Decrease Time to Identify the Species of Candida and bacterial Growth in Cultures.

Use of Raman Spectroscopy to Decrease Time to Identify MRSA Verses MSSA and the Subspecies of Candida and bacterial Growth in Cultures WSU Tech#: 15-1270 Technology Summary: New Technology for the identification of MRSA versus MSSA and sub-species for both bacterial staph Aureus (SA) and Candida in one package, using Raman Spectroscopy. This work...

Published: 2/9/2022 | Inventor(s): Nitin Chouthai

Keywords(s):

Category(s): Imaging, Drug Discovery, Infectious disease, Instrumentation, Software

GENERATION OF 5-FLUOROURACIL + OXALIPLATIN RESISTANT COLON CANCER CELLS: A TOOL TO STUDY CANCER RECURRENCE AND DRUG RESISTANCE

Generation of 5-Fluorouracil + Oxaliplatin Resistant Colon Cancer Cells WSU Tech#: 13-1154 Technology Summary: A significant obstacle for the successful management of patients with colorectal cancer (CRC) is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety...

Published: 11/19/2021 | Inventor(s): Adhip Majumdar, Yingjie Yu

Keywords(s):

Category(s): Biomedical, Biotechnology, Cell lines, Characterization, Drug Discovery, Oncology, Research tools

Long non-protein-coding RNA molecules as therapeutics for epilepsy.

Long Non-Coding RNA Molecules as Therapeutics for Epilepsy WSU Tech#: 12-1089 Technology Summary: Long Non-coding RNA (lncRNA) were first described in 2002 from mouse, making this a relatively new technology. lncRNA transcripts far exceed the number of protein coding mRNAs in the mammalian transcriptome, but in lower copy numbers. Inventors...

Published: 10/5/2023 | Inventor(s): Jeffrey Loeb, Leonard Lipovich

Keywords(s):

Category(s): Medical, Bioinformatics, Biomedical, Biotechnology, Diagnostic, Diagnostics, Drug Discovery, Pharmaceuticals, Therapeutics

CARP-1/CCAR1 Functional Mimetics (CFMs): Novel small molecule suppressors of human breast cancer cell growth.

BackgroundCARP-1 (Cell cycle and apoptosis regulator protein) is a regulator of cell growth signaling. CARP-1 plays an important role in apoptosis (cell death) induction in human breast cancer (HBC) cells in the presence of the chemotherapy agent Adriamycin. The researchers have found that CARP-1 inhibits cell growth by binding with the anaphase...

Published: 8/16/2021 | Inventor(s): Arun Rishi

Keywords(s):

Category(s): Medical, Drug Discovery, Life Science, Oncology, Pharmaceuticals

Topical IL-1Ra (anakinra) in the form of gel to treat persistent diabetic skin and corneal wounds

BackgroundAnakinra (aka. Kineret) is a recombinant human IL-1Ra that was developed by Amgen. It is currently used to treat moderately to severely active rheumatoid arthritis, but also treats neonatal-onset multisystem inflammatory disease (NOMID). Anakinra is given as an IV dose and the drug is no longer under patent. The properties of Anakinra are...

Published: 9/3/2019 | Inventor(s): Fu-Shin Yu

Keywords(s):

Category(s): Biologicals, Drug Discovery, Pharmaceuticals, Therapeutics